Limited coverage drugs – deferasirox

Last updated on October 7, 2022

Special Authority requests can now be submitted online. It's simple and quick!

Learn more or log in.

Generic name	deferasirox
Strength	Tablet, dispersible: 125 mg, 250 mg, 500 mg Tablet, oral: 90 mg, 180 mg, 360 mg
Form	tablet (dispersible and oral)

Generic name

deferasirox

Strength

Tablet, dispersible: 125 mg, 250 mg, 500 mg

Tablet, oral: 90 mg, 180 mg, 360 mg

Form

tablet (dispersible and oral)

Special Authority criteria	Approval period
Treatment of transfusion-dependent conditions where iron chelation therapy is required, according to established criteria*, and when prescribed by a hematologist.	Initial request: 1 year Renewal request: 1 year

Practitioner exemptions

None

Special notes

None

Special Authority request form(s)

* Click on the Special Authority Form below for full criteria:

Log in to eForms
5407 - Deferasirox Coverage - Initial and Renewal (PDF, 360KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage drugs – deferasirox

Practitioner exemptions

Special notes

Special Authority request form(s)